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Abstract
The diagnosis of hypogonadism in human males includes identification of low serum testosterone levels, and hence there is
an underlying assumption that normal ranges of testosterone for the healthy population are known for all ages. However, to
our knowledge, no such reference model exists in the literature, and hence the availability of an applicable biochemical
reference range would be helpful for the clinical assessment of hypogonadal men. In this study, using model selection and
validation analysis of data identified and extracted from thirteen studies, we derive and validate a normative model of total
testosterone across the lifespan in healthy men. We show that total testosterone peaks [mean (2.5–97.5 percentile)] at 15.4
(7.2–31.1) nmol/L at an average age of 19 years, and falls in the average case [mean (2.5–97.5 percentile)] to 13.0 (6.6–25.3)
nmol/L by age 40 years, but we find no evidence for a further fall in mean total testosterone with increasing age through to
old age. However we do show that there is an increased variation in total testosterone levels with advancing age after age
40 years. This model provides the age related reference ranges needed to support research and clinical decision making in
males who have symptoms that may be due to hypogonadism.
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Introduction
In the male, testosterone secretion from the Leydig cells in the
testes has a central role in developing secondary sexual charac-
teristics, supporting spermatogenesis and regulating libido [1].
Synthesis and secretion are under the stimulation of the
gonadotrophin luteinizing hormone (LH) from the anterior
pituitary gland and approximately 98% of circulating testosterone
is bound to plasma proteins, with the remaining 2% circulating
freely [2]. Whether healthy adult men maintain serum testosterone
concentrations throughout life, and the implications of a
postulated decline and thus its potential for therapy, have been
widely debated but remain unclear [3,4].
A number of studies have reported decreasing testosterone levels
in men with age. This includes a study involving both cross-
sectional and longitudinal components [5], that reported low levels
(,11.3 nmol/L) of total testosterone in up to 20% of men over 60,
30% over 70 and 50% over 80 years of age and suggested that
further investigation of testosterone replacement in aged men,
perhaps targeted to those with the lowest serum testosterone
concentrations, was justified [5]. Longitudinal observation in the
Massachusetts Male Aging Study also showed a decrease in total
testosterone (TT) with increasing age [6], particularly when
accompanied by increasing obesity. Male hypogonadism is a
clinical condition resulting from testosterone deficiency as a result
of abnormalities of testicular, hypothalamic or pituitary function.
The diagnosis is based on clinical and biochemical findings and
has been shown to be associated with impaired sexual function,
impaired cognitive function [7,8], depression [9], abdominal
obesity, low bone and muscle mass [10], diabetes, and prediabetic
states (including insulin resistance, impaired glucose tolerance and
the metabolic syndrome) that may lead to an increase in risk of
cardiovascular disease [11–13]. Overall, cardiovascular mortality
is increased in late-onset hypogonadism [14,15]. Testosterone
replacement in young hypogonadal men results in significant
improvement of libido and sexual function and is of clear benefit
[16], but it remains to be established in older men that general
health and other manifestations of the metabolic syndrome are
improved [17–19]. Testosterone replacement therapy in older
hypogonadal men is associated with an increased risk of
cardiovascular events [20,21], and such concerns have led to a
current reappraisal of the safety of testosterone replacement
(http://www.fda.gov/drugs/drugsafety/ucm383904.htm).
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As the diagnosis of hypogonadism includes identification of
serum testosterone levels below the normal range for healthy
males, there is an underlying assumption that normal ranges of
testosterone for the healthy population are known for all ages.
However, to our knowledge, no such reference model exists in the
literature, and hence the identification of individuals as hypogo-
nadal does not have a widely applicable biochemical basis. In this
study we derive and validate a normative model of TT across the
lifespan.
Methods
Data acquisition
Using an established methodology [22–24], studies containing
TT measurements of healthy human males at a known age were
identified by performing Medline and Embase searches, using the
search terms Humans, Testosterone, Males and Reference values.
The reference lists of selected studies were checked, and cited
references were retrieved to identify further relevant studies.
Manuscripts were included for analysis if they reported TT levels
for healthy normal males with no known testicular or endocrino-
logical disorders. Data from subjects with an identified chronic
illness or on testosterone replacement therapy were excluded from
the dataset, as were data from fetal blood and cord blood. These
studies provided the basis for a dataset for TT that approximates
the healthy human population from childhood to old age. Twenty-
seven studies were identified that met the inclusion criteria; eleven
studies were excluded because only descriptive statistics for study
data were reported [25–35].
For the remaining sixteen studies, data were extracted from
scatterplots using Web Plot Digitizer v2.6 (http://arohatgi.info/
WebPlotDigitizer) to convert the datapoints into pairs of numerical
values denoting age and TT (n= 10,458; age range 0–101 years).
Two researchers (TWK & LQL) extracted data from each plot
with the results being compared (a) for inter-observer agreement
and (b) agreement with the published descriptive statistics. Inter-
observer agreement limits were set at 99% for both age and TT
levels; in the event that this limit was not reached due to observer
or calibration error, the data were extracted again by both
observers. Longitudinal data were recorded as cross-sectional
values. Serum testosterone values were standardised to give units
of testosterone in nmol/L using the standard multiplication factor
1 ng/dL=0.0347 nmol/L.
The current gold standard assay for male testosterone is mass
spectroscopy-based LC-MS/MS [36], and several of our data
sources measured testosterone using non-extraction platform
immunoassays. A recent analysis of serum testosterone measure-
ments (n = 3,174) comparing one such platform immunoassay
demonstrated good accuracy at all concentrations found in
eugonadal as well as hypogonadal men, when compared to mass
spectroscopy assay values [37]. A further search of the biomedical
literature was therefore performed to identify conversion formulae
from other assay values to LC-MS/MS values [38–40], so that our
modelling is concordant with current endocrinological best
practice. Since the conversions used correlate strongly (85%–
97%, Table 1) and have small Bland-Altman mean differences
[41], their use introduces no significant bias into the combined
data. For three of our identified studies [42–44], no such
conversion formula was found (in-house assays were used and no
direct comparison with LC-MS/MS values was made), and their
data were therefore excluded. Data were also censored at age 3
years: extracted values below this age failed to match the
descriptive statistics published with the chart, and therefore could
not be used to model accurately the height or age of the expected
peak in TT in early infancy.
The final dataset (n = 10,097; age range 3–101 years) obtained
from 13 studies (Table 1) represents a typical random sample from
the healthy male population, and was used as the basis for
normative model selection and verification. All data in this study
were extracted from existing publications in the scientific and
medical literature. Data relating to individual human subjects was
not included and therefore specific ethical approval was not
required.
Data analysis
Zero TT values at conception were added to the combined
dataset, in order to force models through the only known level at
any age; these values were not taken into account when calculating
Table 1. Total testosterone data summary.
Ref 1st Author Assay Conversion formula r Conversion source n Ages
[57] Abdelrahaman DPC y = 1.098x20.1 0.92–0.97 Wang et al. 47 6.2 (4.9–9.0)
[58] Bergada DSL y = 1.791x20.178 0.85 Scaglia y col. 94 0.02 (0–0.1)
[59] Elmlinger Centaur y = 1.195*x20.05 0.92–0.97 Wang et al. 623 40.1 (0–98.9)
[28] Friedrich Centaur y = 1.195*x20.05 0.92–0.97 Wang et al. 971 47.4 (20.3–79.8)
[60] Kyriakopoulou LS-MS/MS NA NA NA 172 8.3 (0–18.6)
[61] Leifke DSL y = 1.791x20.178 0.85 Scaglia y col. 572 40.5 (20.0–80.0)
[5] Mitchell Harman DSL y = 1.791x20.178 0.85 Scaglia y col. 890 56.9 (22.9–94.4)
[49] Morley DPC y = 1.098x20.1 0.92–0.97 Wang et al. 287 76.2 (61.2–101.1)
[29] Yeap DPC y = 1.098x20.1 0.92–0.97 Wang et al. 3645 76.6 (70.8–87.8)
[62] Pierik Centaur y = 1.195x20.05 0.92–0.97 Wang et al. 113 0.22(0.1–0.4)
[26] Halmenschlager Roche y = 1.167x22.62 0.92–0.97 Wang et al. 428 51.9 (29.8–83.0)
[63] Sartorious LS-MS/MS NA NA NA 324 59.8 (40.1–86.9)
[6] Travison RIA x = 0.706y1.077 0.96 Janse et al. 2194 61.5 (44.9–80.0)
The 13 papers listed were used as data sources, identified by reference number and first author. In the conversion formulae, x denotes the study assay and y denotes LS-
MS/MS; r denotes the published correlation coefficient for the conversion formula. Median and range of ages are in years. NA denotes not applicable since no
conversion is needed.
doi:10.1371/journal.pone.0109346.t001
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model errors and fit. Since variability increases with testosterone
level, the data were log-adjusted (after adding one to each value so
that zero testosterone on a chart represents zero testosterone level).
We then fitted 330 mathematical models to the data using
TableCurve-2D (Systat Software Inc., San Jose, California, USA),
and ranked the results by coefficient of determination, r2. Each
model defines a generic type of curve and has parameters which,
when instantiated gives a specific curve of that type. For each
model we calculated values for the parameters that maximise the
r2 coefficient. The Levenberg-Marquardt non-linear curve-fitting
algorithm was used throughout, with convergence to 9 significant
figures after a maximum of 4,000 iterations, for models having up
to 21 parameters. For each candidate model, the mean square
error and r2 were calculated after removing the artificial zero
values at conception. In addition LOESS regression [45] was used
to investigate the possibility that the best predictive model may be
an ensemble of locally linear or quadratic models, rather than a
single model covering all age ranges.
The best performing family of models were rational polynomi-
als. 5-fold cross validation was performed: the data were randomly
split into 5 equally sized subsets. For each subset S, the other four
subsets were used to train rational polynomials having 3–11
parameters, with subset S being held back as test data. The mean
square error of the test data was calculated and compared to the
mean square error of training data for the same model. In other
words, the estimated prediction error of a model when generalized
to unseen data was compared to the training error of the model. A
model was considered validated if
1. the residuals of the test data were approximately normally
distributed, and
2. the tradeoff between high r2 for the training data (denoting
possible overfitting to the data) and low generalisation error for
the unseen test data (denoting possible underfitting to the data)
was optimal.
Results
The validated model is a rational polynomial of the form
log10 TTz1ð Þ~
azcxzex2zgx3
 
= 1zbxzdx2zfx3
 
where TT is measured in nmol/L and x denotes age in years.
Model coefficients a – f are given in Table 2, and relationship to
the data given in Figure 1. The model has coefficient of
determination r2 = 0.41 indicating that around 41% of the
variation in serum TT throughout healthy male life is due to
age alone, and that 59% in the variation is therefore due to other
factors such as lifestyle, anthropometry and health status. The r2
for the best-fitting LOESS model was 0.32, establishing the
optimality of the single regression model in terms of goodness-of-
fit. The residual plot for the validated model (Figure 2) shows a
distribution close to the ideal Gaussian curve (r2 = 0.99). More-
over, the proportions of residuals within one, two and three
standard deviations (respectively 71%, 96% and 99%) are close to
the expected values for data with a Gaussian distribution
(respectively 68%, 95% and 99%). Figure 3 is an exemplar of
the 5-fold validation process in which a model is chosen that
neither overfits nor underfits the underlying dataset.
Our log-unadjusted normative model (Figure 4) provides
average TT values for the entire age range, together with
normative ranges in terms of standard deviations away from
age-related mean levels. The same model is given in terms of
centiles in Figure 5. Residual plots for each decade of age are
supplied as supporting information (Figure S1a–h), as are the
remaining cross-validation plots (Figure S2), and the TableCurve
inputs and output for the validated model (Table S1). Mean and
normative ranges for serum TT in healthy males are given for ages
from 3 to 88 years in Table 3.
We show that TT peaks [mean (2.5–97.5 percentile)] at 15.4
(7.2–31.1) nmol/L at an average age of 19 years, and falls in the
average case [mean (2.5–97.5 percentile)] to 13.0 (6.6–25.3) nmol/
L by age 40 years, but we find no evidence for a further fall in
mean TT with increasing age through to old age. However we do
show that there is an increased variation in TT levels with
advancing age after age 40 years. Our analyses show that the 95%
prediction limit increases from 18.7 nmol/L at age 40 years to
24.5 nmol/L at age 88 years. The model provides centile and/or
standard score values for an individual when compared to the
population as a whole.
Discussion
Using data-driven modelling and analysis, we have derived a
normative model of total testosterone throughout the lifespan. We
have shown that in the average healthy male testosterone is low in
pre-puberty, rises from age 11 and peaks at age 19 at 15.4 (7.2–
31.1) nmol/L [mean (2.5–97.5 percentile)]. Thereafter TT falls
slightly to age 40 years to 13.0 (6.6–25.3) nmol/L. We find no
evidence to support a progressive decline in testosterone in middle-
aged and older men, sometimes termed the ‘andropause’, as TT
does not fall significantly in the average man after the age of 40
years. Our analyses show that the 95% prediction limit increases
Table 2. Model parameter values.
Parameter Value Std Error T Value 95% Conf Lim 95% Conf Lim2
a 0.04655 0.00718 6.48262 0.03247 0.06063
b 20.05311 0.00748 27.09759 20.06777 20.03844
c 0.05123 0.00629 8.15049 0.03891 0.06355
d 20.00793 0.00142 25.59626 20.01070 20.00515
e 20.01222 0.00148 28.25065 20.01513 20.00932
f 0.00058 0.00007 8.01130 0.00044 0.00072
g 0.00069 0.00008 8.49093 0.00053 0.00085
Also given are the standard error and T statistic for the values, and the upper and lower 95% confidence limits for the values.
doi:10.1371/journal.pone.0109346.t002
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from 18.7 nmol/L at age 40 years to 24.5 nmol/L at age 88 years.
This increase in variation with increasing age demonstrates that
reference ranges for TT that do not take chronological age into
account are inappropriate for the assessment of an individual’s
testosterone levels.
Previous studies of TT have reported contradictory results.
Whilst some studies show a decline in serum TT with age
throughout life, other studies report no change in testosterone
levels after approximately age 35 years. In particular, from the
studies used as a basis for our dataset, Travison et al. [6] observed
a cross-sectional decline of 0.4% per year age from 45 years
Figure 1. The validated model, log-adjusted testosterone values. Our dataset (n = 10,098) of log-adjusted observed total testosterone for
ages 3–88 years, split into normative ranges determined by mean predicted values (blue line) and one (red), two (blue), three (green), and four
(purple) standard deviations higher and lower than the predicted values.
doi:10.1371/journal.pone.0109346.g001
Figure 2. Residual analysis. The residuals are the variations in log-adjusted observed values from the log-adjusted age-related mean value
predicted by the model. The residuals have excellent goodness of fit to an ideal Gaussian curve (r2 = 0.99). 71% of the residuals are within one
standard deviations (SD) of the mean, 95% within 2 SD, and 99% within 3SD. The percentages for an ideal Gaussian distribution are 68%, 95% and
99% respectively.
doi:10.1371/journal.pone.0109346.g002
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onwards in 2,194 men (95% CI of 0.2% to 0.6%), whereas Yeap et
al. [29] found that TT did not decline with advancing age in older
men (aged 70–89, n= 3,645). Halmenschlager et al. (n = 428) [26]
report both no decline in TT with advancing years and an increase
in variance later in life. Our analysis of the combined data from 13
studies shows that TT levels do not decline after age 40 years in
the average case.
We now compare our results with those reported in studies that
were not used to form our dataset. These comparisons are
necessarily qualitative since the data were in the form of
descriptive statistics or could not be reliably converted to the
LC-MS/MS assay and hence were excluded during our data
acquisition process. For each study we supply the number of
subjects involved, n, to aid comparison with the studies used as a
basis for our dataset. Rohmann et al. [27] report a decline of 1.0%
per year from age 35 (n= 1,351), in qualitative disagreement to
our findings. However they report geometric means as opposed to
arithmetic means and do not report the sample size for each
calculation, so a detailed comparison of their results to ours is not
possible. Muller et al. [32], Mohr et al. [31] and Simon et al. [35]
all report a small annual decline of 0.4%, 0.3% and 0.5%
respectively (n = 400, 1,677, 1,408 respectively) and show no
Figure 3. Exemplar of model validation stage. High test and training errors represent underfit (i.e. insufficient model parameters to accurately
capture essential features of the dataset), and high test errors represent overfit (i.e. a model that will not generalise to accurately predict new data).
The optimal number of model parameters is seven in this instance, and in the analysis of the four other cross validation sets.
doi:10.1371/journal.pone.0109346.g003
Figure 4. The validated model. Our dataset (n = 10,098) of observed total testosterone for ages 3–88 years, split into normative ranges
determined by mean predicted values (blue line) and one (red), two (blue), three (green), and four (purple) standard deviations higher and lower than
the predicted values.
doi:10.1371/journal.pone.0109346.g004
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increase in variance, also in qualitative disagreement with our two
key findings. Frost et al. [25], Boyce et al. [46] and Orwoll et al.
[30] (n = 783, 266, 2,623 respectively) all report no decline in
serum TT with advancing age but also no increase in variance.
Rhoden et al. [34] report that not only does serum TT not fall
with advancing age, but there is also an increase in variance across
the lifespan from age 40 onwards (n = 1,071). Taken together,
these studies provide partial qualitative external validation for our
model, but do not completely resolve the issue of contradictory
single-centre study outcomes.
Our model is derived from data from multiple sources of the
measurement of TT in over 10,000 healthy males aged between 3
and 101 years. This is both a strength and weakness of the study.
The strength is that modelling power is increased by the provision
of large numbers of datapoints for a wide range of ages: it has been
previously shown that models that include both prepubertal,
pubertal and adult ages can be used to derive important insights
for a restricted age range [47]. The weakness is the approximate
heterogeneity of the values obtained from diverse sources,
especially as assay conversion factors were used that have known
high correlation but are nevertheless inexact. This includes studies
that involve convenience samples (e.g. primary care and out-
patient attenders) as well as those that involve population derived
cohorts. Further limitations of our approach are that insufficient
data were found to model accurately neonatal ages, and that we
had to exclude potentially useful studies that used in-house assays
which lack standardisation and harmonisation, and for which no
conversion formula has been published [48]. Ten of the thirteen
studies used as data sources (Table 1) excluded subjects taking
medication that could affect the endocrine system, but three
studies [5,6,49] (combined n= 2,371 of 10,097) do not have
equivalently explicit inclusion criteria. We can therefore not rule
out the possibility that a small number of subjects were on
medication that increased their TT levels.
Our results suggest that the reported increase in the proportion
of hypogonadal men with increasing age can be attributed to the
increase in variance of testosterone levels with increasing age, as
opposed to an age-related decline in testosterone levels for the
population as a whole. In particular, our model provides a
coherent explanation for the widely believed but incorrect
assertion that the prevalence of male hypogonadism increases
from 12% in men in their 50s to 49% in men in their 80s when
hypogonadism is defined as a TT level lower than the 2.5
percentile [5,50], or lower than 6.4 nmol/L using the LC-MS/MS
assay. These assertions are incorrect since it is not possible to have
more than 2.5% of the population included in an age-related 2.5th
centile. However, if the definition of hypogonadism is based on a
TT level lower than a fixed value, then the prevalence of
hypogonadism will indeed increase due to increased variance with
advancing age. A common rationale for the increased prevalence
of low serum testosterone levels is the assertion of an annual
average case decline of 1% or more [6,50]. As shown above, the
majority of cross-sectional studies either report no decline in the
average case, or a moderate annual decline in testosterone levels.
Again, the disparity between the common explanation given and
the data in the literature is that a greater proportion of individuals
have lower levels of testosterone with increasing age.
There is disagreement on the indications for the use of
hormonal therapy in men with apparently age-related low
testosterone concentrations [51,52]. Our analysis of the combined
data from several studies agrees to a certain extent with both sides
of the controversy. We find no evidence that TT declines in the
average case after the age of 40 years for ageing males. We do find
that the prevalence of higher and lower testosterone levels
increases with age, and hence that there is a larger number of
men potentially at risk of androgen-related disorders. Our study
shows that the increasing proportion of men commonly regarded
as having abnormally low (or high) levels of TT can be accounted
for by the increase in variance in testosterone levels with age.
Factors that have been identfied as determinants of lower
testosterone include obesity in many studies, as well as the
development of other co-morbidities [53–55]. Obesity was not an
exclusion criteria for our data acquistion, and our age-related
reference ranges can be used for quantitative evaluation of the
relationship between high body-mass index and low testosterone.
There is increasing concern over testosterone supplementation in
Figure 5. The validated model in centiles. Normative ranges for the model of total testosterone from ages 3–88 years. In the average case (red
line) total testosterone remains constant for age .40. However, the variance in normative ranges increases for these ages, with 1st to 99th centile
ranges of 5.6–27.6 nmol/L at age 35 years and 4.1–33.1 nmol/L at age 88 years.
doi:10.1371/journal.pone.0109346.g005
A Validated Age-Related Normative Model for Male Total Testosterone
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men, both generally and more particulary in those with
comorbidities [20,21]. Whether all or subgroups of older
hypogonadal men might benefit from replacement requires critical
assessment, for which a robustly-established normal range
provides an important basis.
This analysis also highlights the increasing proportion of men
with high testosterone with increasing age. This intriguing finding
is both at odds with the notion of an age-related fall in the general
case, and may be relevant to diseases more prevalent in this age
group. For example, a recent study has shown an association in
older men between high testosterone and increased all-cause
mortality when compared to those with mid-range testosterone
levels [56], although causality or indeed reverse causality are not
established.
In conclusion, This model provides the reference ranges needed
to support research and clinical decision making in males who
have symptoms that may be due to hypogonadism. In addition,
our study suggests that instead of a gradual decline in testosterone
levels in men as they age there is an increasing variation in
testosterone levels in aged men with a larger population of
hypogonadal males, who may benefit from testosterone therapy,
but also more men with high serum total testosterone that may
also be disadvantageous [56].
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